BioNTech SE BNTX

$BNTX $MRNA $NVAX
And here’s data from Qatar. $BNTX is without doubt the best vaccine in the market, across all Covid variants:
https://www.washingtonpost.com/health/2021/05/05/pfizer-vaccine-virus-variants/

$BNTX $MRNA $NVAX

Meanwhile here’s some serious data from Israel:

https://www.independent.co.uk/news/health/pfizer-vaccine-coronavirus-israel-data-b1842617.html

Jamal your dumb strategy to dampen confidence is not working. All it is doing is making you look like the fucking moron that you are.

125$ is good entry point

$BNTX
Av Est. EPS: $32.07 (‘21) and $18.69 (‘22)
Av Est. Revenue: $12.29B (‘21) and $7.73B (‘22)
Market Cap @ SP 180: $42.3B
P/E @ SP 180: 9.63 (based on ‘22 EPS)

$MRNA
Av Est. EPS: $23.27 (‘21) and $16.58 (‘22)
Av Est. Revenue: $17.46B (‘21) and $13.69B (‘22)
Market Cap @ SP 180: $72.2B
P/E @ SP 180: 10.88 (based on ‘22 EPS)

Looks like market is grossly underestimating revenue & EPS for $BNTX. Once revenue and EPS for this and next year for $BNTX becomes clear there will be a major price correction. If $BNTX has higher revenue and higher earnings it should have a higher market cap, so price should be more than 2x that of $MRNA.

https://www.msn.com/en-gb/health/medical/nipah-virus-panic-as-deadly-pathogen-with-no-cure-sweeps-across-asia-new-pandemic-fears/ar-BB1gbHGU?ocid=msedgntp

Bharat Biotech's Covaxin found 100% effective against 'severe Covid disease' in Phase-3 interim analysis

O. M. G.

This is huge ! IMO.

OMG!!!!

??????????????????

Time to shift some to $COIN

@Chris, you can’t value company based on stock price alone. A better indicator is marketcap.

@Henrigue agreed. You can’t mix vaccines. They are likely alternate the combinations of 3-4 vaccines.